Santen and aerie conclude exclusive license agreement for rhopressa® and rocklatan® in japan and several other asian countries

Osaka, japan & durham, n.c.--(business wire)--santen pharmaceutical co., ltd. (“santen”) and aerie pharmaceuticals, inc. (nasdaq: aeri, “aerie”) announced that santen and aerie have entered into an exclusive development and commercialization agreement for rhopressa® and rocklatan® in japan, along with rights for several other asian countries. aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
AERI Ratings Summary
AERI Quant Ranking